Avecho Biotechnology Ltd (AVE)

AVE Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

AVE's Principal Activity is the development, production, sale and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skin care and animal health and nutrition industries.

Announcements

Company Overview

Dividend History

Ex-Date	Amount	Franking	Gross	Type	Payable
22/09/2010	$0.03	0%	$0.03	Final	21/10/2010
26/02/2010	$0.02	0%	$0.02	Interim	24/03/2010
30/09/2009	$0.02	0%	$0.02	Final	21/10/2009
26/02/2009	$0.02	0%	$0.02	Interim	31/03/2009

Show All

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM)	$0.00
Gross DPS(TTM)	$0.00
Dividend yield
Gross yield
Payout Ratio	--
DRP	No
DRP Features	-

Directors & Management

Name	Title	Since	Bio
Dr Paul Gavin	Chief Executive Officer	May 2020
Mr Matthew Patrick McNamara	Non-Executive Director	Jan 2020	Mr Matthew Patrick McNamara Non-Executive Director Mrt McNamara has over 30 years' experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in, Avita Medical Ltd, Bioxyne Ltd, and Rex Bionics Pty Ltd. He has also served as CIO of BioScience Manager Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co.
Dr Gregory (Greg) Collier	Non-Executive Chairman,Non-Executive Director	Apr 2019	Dr Gregory (Greg) Collier Non-Executive Chairman,Non-Executive Director Dr Collier has more than 20 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has taken a drug from discovery through to regulatory approval. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto.
Ms Melanie Jaye Leydin	Chief Financial Officer,Company Secretary	Dec 2018
Mr David Segal	Non-Executive Director	May 2016	Mr David Segal Non-Executive Director Mr Segal was the Investor Relations Manager at Phosphagenics from 2011 to 2015. Prior to this he worked for over 30 years in stockbroking, including setting up, raising capital for and running Trent Securities which was absorbed into Shaw Stockbroking in 1992. Mr Segal has been a shareholder of Phosphagenics since 1999.
Dr Ross Murdoch	Non-Executive Director	Apr 2015	Dr Ross Murdoch Non-Executive Director Dr Murdoch joined Phosphagenics as CEO in January 2015 and was appointed as director in April 2015. He has more than 25 years' experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals where he founded and grew both the Emerging Products Business and Haematology Business, and President and COO of Prana Biotechnology Limited based in Australia.
Paul Gavin	Chief Executive Officer	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Ross Murdoch	31/12/2020	1,666,667	N/A	N/A	N/A
David Segal	31/12/2020	11,795,920	6,695,361	N/A	N/A
Gregory (Greg) Collier	31/12/2020	N/A	2,000,000	2,250,000	N/A
Matthew McNamara	13/01/2020	0	N/A	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Mr Mark Gregory Kerr & Mrs Linda Marie Kerr (Lindmark Inv Staff S/F A/C)	159,684,474	8.73%
HSBC Custody Nominees (Australia) Limited	102,104,170	5.58%
Rosscope Pty Ltd (Ross Copeland Family A/C)	78,921,263	4.32%
Mr Mark Gregory Kerr (Lindmark Inv Staff S/F A/C)	67,153,797	3.67%
Melbourne Securities Corporation Limited (Horizon 3 Bioteh Fund A/C)	45,454,545	2.49%
BNP Paribas Noms Pty Ltd (Drp)	35,325,418	1.93%
Servbond Pty Limited (Servbond Pty Ltd S/F A/C)	23,050,000	1.26%
Citicorp Nominees Pty Limited	22,547,403	1.23%
Ack Pty Ltd (Markoff Super No 2 A/C)	20,494,147	1.12%
Churchcourt Pty Limited	20,162,500	1.10%
Kazakco Pty Ltd (Kent Family A/C)	20,000,000	1.09%
Mr Tony Domenic Amato	19,500,712	1.07%
Mr Ross Graham Copeland & Mrs Gina Copeland (Publicity Press S/F A/C)	16,868,545	0.92%
Dr Maurice Arthur Trewhella & Mrs Elizabeth Trewhella (Simpetejen Super Fund A/C)	16,000,000	0.87%
Mrs Susan Margaret Chudleigh & Mr John West Chudleigh	15,000,000	0.82%
Bhl Pension Pty Ltd (Bhl Pension Fund A/C)	15,000,000	0.82%
Mr Gary Dean Shaw	15,000,000	0.82%
Mr Brandon Armon Batagol	13,932,870	0.76%
Gold Road Orient Holdings Pty Ltd	12,500,000	0.68%
Bagbo Pty Ltd	11,896,159	0.65%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.007	30 June
2019	$0.003	28 June

AVE Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.